1
|
Eldin C, Nurtop E, Coiffard B, Colombini N, Ninove L, Priet S, Barthélémy K, Reynaud-Gaubert M, de Lamballerie X. Correspondence: serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2 and BA.5 in lung transplant recipients receiving prophylactic tixagevimab/cilgavimab. Infection 2024:10.1007/s15010-024-02258-1. [PMID: 38584221 DOI: 10.1007/s15010-024-02258-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 04/02/2024] [Indexed: 04/09/2024]
Affiliation(s)
- Carole Eldin
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
- Comité de Lutte Contre les Infections Nosocomiales (CLIN) Équipe Opérationnelle d'Hygiène (EOH), Hôpital Nord, Assistance-Publique Hôpitaux de Marseille, Marseille, France.
| | - Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Benjamin Coiffard
- Service de Pneumologie et Équipe de Transplantation Pulmonaire, Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) Adulte, AP-HM Hôpital Nord, 13015, Marseille, France
- Aix Marseille Université, Marseille, France
| | - Nathalie Colombini
- Pharmacy Department, North Hospital, Public Hospitals of Marseille, Aix-Marseille University, Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Karine Barthélémy
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Martine Reynaud-Gaubert
- Service de Pneumologie et Équipe de Transplantation Pulmonaire, Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) Adulte, AP-HM Hôpital Nord, 13015, Marseille, France
- Aix Marseille Université, Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| |
Collapse
|
2
|
Inchauste L, Nurtop E, Brisbarre N, Ninove L, Gallian P, de Lamballerie X, Priet S. Exploring cell-free assays for COVID-19 serosurvey. Sci Rep 2024; 14:6096. [PMID: 38480769 PMCID: PMC10938000 DOI: 10.1038/s41598-024-55852-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 02/28/2024] [Indexed: 03/17/2024] Open
Abstract
Serosurveys to monitor immunity toward COVID-19 in the population are primarily performed using an ELISA to screen samples for SARS-CoV-2 antibodies, followed by confirmation by a virus neutralization test, which is considered the Gold Standard. However, virus neutralization test may not be feasible for some laboratories because of the requirement for specific facilities and trained personnel. In an attempt to address this limitation, we evaluated three cell-free methods as potential alternatives for assessing SARS-CoV-2 seroprevalence in human population from plasma. We report the establishment of two inhibition ELISAs designed to detect anti-Spike RBD IgG antibodies and a microsphere quantitative suspension array technology assay, based on the Luminex xMAP platform, to measure the presence of antibodies against various SARS-CoV-2 antigens, including anti-RBD. These methods were also compared to a commercial chemiluminescent immunoassay designed for anti-RBD antibodies detection and to the combined ELISA + virus neutralization test strategy. These cell-free assays performed equally to estimate the percentage of positive and negative samples and could be used to determine the prevalence of SARS-CoV-2 antibodies in human population, at least in cohort with high-expected prevalence, without the use of seroneutralization assay.
Collapse
Affiliation(s)
- Lucia Inchauste
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Nadège Brisbarre
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
- Établissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
- Établissement Français du Sang, La Plaine Saint-Denis, Saint-Denis, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
| |
Collapse
|
3
|
Kraft TS, Seabright E, Alami S, Jenness SM, Hooper P, Beheim B, Davis H, Cummings DK, Rodriguez DE, Cayuba MG, Miner E, de Lamballerie X, Inchauste L, Priet S, Trumble BC, Stieglitz J, Kaplan H, Gurven MD. Metapopulation dynamics of SARS-CoV-2 transmission in a small-scale Amazonian society. PLoS Biol 2023; 21:e3002108. [PMID: 37607188 PMCID: PMC10443873 DOI: 10.1371/journal.pbio.3002108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Accepted: 07/17/2023] [Indexed: 08/24/2023] Open
Abstract
The severity of infectious disease outbreaks is governed by patterns of human contact, which vary by geography, social organization, mobility, access to technology and healthcare, economic development, and culture. Whereas globalized societies and urban centers exhibit characteristics that can heighten vulnerability to pandemics, small-scale subsistence societies occupying remote, rural areas may be buffered. Accordingly, voluntary collective isolation has been proposed as one strategy to mitigate the impacts of COVID-19 and other pandemics on small-scale Indigenous populations with minimal access to healthcare infrastructure. To assess the vulnerability of such populations and the viability of interventions such as voluntary collective isolation, we simulate and analyze the dynamics of SARS-CoV-2 infection among Amazonian forager-horticulturalists in Bolivia using a stochastic network metapopulation model parameterized with high-resolution empirical data on population structure, mobility, and contact networks. Our model suggests that relative isolation offers little protection at the population level (expected approximately 80% cumulative incidence), and more remote communities are not conferred protection via greater distance from outside sources of infection, due to common features of small-scale societies that promote rapid disease transmission such as high rates of travel and dense social networks. Neighborhood density, central household location in villages, and household size greatly increase the individual risk of infection. Simulated interventions further demonstrate that without implausibly high levels of centralized control, collective isolation is unlikely to be effective, especially if it is difficult to restrict visitation between communities as well as travel to outside areas. Finally, comparison of model results to empirical COVID-19 outcomes measured via seroassay suggest that our theoretical model is successful at predicting outbreak severity at both the population and community levels. Taken together, these findings suggest that the social organization and relative isolation from urban centers of many rural Indigenous communities offer little protection from pandemics and that standard control measures, including vaccination, are required to counteract effects of tight-knit social structures characteristic of small-scale populations.
Collapse
Affiliation(s)
- Thomas S. Kraft
- Department of Anthropology, University of Utah, Salt Lake City, Utah, United States of America
- Department of Anthropology, University of California Santa Barbara, Santa Barbara, California, United States of America
- Department of Human Behavior, Ecology, and Culture, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany
| | - Edmond Seabright
- School of Collective Intelligence, Mohammed VI Polytechnic University, Rabat, Morocco
- University of New Mexico, Department of Anthropology, Albuquerque, New Mexico, United States of America
| | - Sarah Alami
- Department of Anthropology, University of California Santa Barbara, Santa Barbara, California, United States of America
- School of Collective Intelligence, Mohammed VI Polytechnic University, Rabat, Morocco
| | - Samuel M. Jenness
- Department of Epidemiology, Emory University, Atlanta, Georgia, United States of America
| | - Paul Hooper
- Department of Health Economics and Anthropology, Economic Science Institute, Argyros School of Business and Economics, Chapman University, Orange, California, United States of America
| | - Bret Beheim
- Department of Human Behavior, Ecology, and Culture, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany
| | - Helen Davis
- Department of Human Evolutionary Biology, Harvard University, Cambridge, Massachusetts, United States of America
| | - Daniel K. Cummings
- Department of Health Economics and Anthropology, Economic Science Institute, Argyros School of Business and Economics, Chapman University, Orange, California, United States of America
| | | | | | - Emily Miner
- Department of Anthropology, University of California Santa Barbara, Santa Barbara, California, United States of America
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ–IRD 190 –Inserm 1207 –IHU Méditerranée Infection), Marseille, France
| | - Lucia Inchauste
- Unité des Virus Émergents (UVE: Aix-Marseille Univ–IRD 190 –Inserm 1207 –IHU Méditerranée Infection), Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ–IRD 190 –Inserm 1207 –IHU Méditerranée Infection), Marseille, France
| | - Benjamin C. Trumble
- School of Human Evolution and Social Change, Arizona State University, Tempe, Arizona, United States of America
- Center for Evolution and Medicine, Arizona State University, Tempe, Arizona, United States of America
| | | | - Hillard Kaplan
- Department of Health Economics and Anthropology, Economic Science Institute, Argyros School of Business and Economics, Chapman University, Orange, California, United States of America
| | - Michael D. Gurven
- Department of Anthropology, University of California Santa Barbara, Santa Barbara, California, United States of America
| |
Collapse
|
4
|
Touret F, Martin-Blondel G, de Lamballerie X, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, N'Guyen S, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Barthélémy K, Priet S, Nurtop E, Sanchez VP, Tardivon C, Blancho G, Le Bourgeois A, Lévy V. Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg. J Infect 2023; 86:e126-e129. [PMID: 36750165 DOI: 10.1016/j.jinf.2023.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2023] [Accepted: 02/02/2023] [Indexed: 02/07/2023]
Affiliation(s)
- Franck Touret
- Unité des Virus Émergents, INSERM-1207, IRD-190, Aix-Marseille University, France
| | - Guillaume Martin-Blondel
- Service des Maladies Infectieuses et Tropicales, CHU de Toulouse & Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, France
| | | | - Axelle Dupont
- Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France; Centre d'Investigation clinique-Epidémiologie Clinique 1425, Inserm, Hôpital Bichat, Paris, France; Department of Epidemiology Biostatistics and Clinical Research, AP-HP, Hôpital Bichat, Paris, France
| | - Jacques Izopet
- CHU Toulouse, Hôpital Purpan, Laboratoire de Virologie, National Reference Center for Hepatitis E, 31300 Toulouse, France; Inserm UMR 1291, CNRS UMR5051, Université Toulouse III, 31000 Toulouse, France
| | - France Mentré
- Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France; Centre d'Investigation clinique-Epidémiologie Clinique 1425, Inserm, Hôpital Bichat, Paris, France; Department of Epidemiology Biostatistics and Clinical Research, AP-HP, Hôpital Bichat, Paris, France
| | - Nassim Kamar
- Département de Néphrologie et Transplantation d'Organes, CHU Rangueil 31059 Toulouse, France
| | - Brigitte Autran
- Sorbonne-Université, Cimi-Paris, Inserm U1135, CNRS ERL8255, UPMC CR7, Team "NK and T Cell Immunity, Infections and Cancer", Paris, France
| | - Gilles Paintaud
- Université de Tours, EA4245 Transplantation, Immunology and Inflammation, Tours, France
| | - Sophie Caillard
- Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France; Inserm UMR S1109 Labex Transplantex, Fédération de Médecine Translationnelle, Strasbourg University, Strasbourg, France
| | - Christophe Richez
- Hôpital Pellegrin, CHU de Bordeaux, Service de Rhumatologie, Centre de référence des maladies autoimmunes systémiques rares (RESO), UMR-CNRS 5164, Université de Bordeaux, Bordeaux, France
| | - Lionel Couzi
- Nephrologie-Transplantation-Dialyse, CHU Bordeaux, Bordeaux, France; CNRS-UMR 5164 Immuno ConcEpT, Université de Bordeaux, Bordeaux, France
| | - Aliénor Xhaard
- Service d'hématologie greffe Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France
| | - Zora Marjanovic
- Sorbonne University, Paris, France; Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France; INSERM, UMRs 938, Paris, France
| | - Jerome Avouac
- Université de Paris Service de Rhumatologie, Hôpital Cochin, AP-HP, CUP 27 rue du Faubourg Saint-Jacques 75014 Paris, France
| | - Caroline Jacquet
- Service d'Hématologie, CHRU Nancy, Hôpitaux Brabois, Vandoeuvre les Nancy, France
| | - Dany Anglicheau
- Department of Nephrology and kidney transplantation, Necker Hospital, APHP and Université de Paris Cité, Paris, France
| | - Morgane Cheminant
- Clinical Hematology, Necker-Enfants Malades University Hospital, AP-HP, F-75015, Université de Paris Cité, Paris, France
| | | | - Stéphanie N'Guyen
- Sorbonne université, Groupe Hospitalier Pitié-Salpêtrière APHP, Service d'Hématologie clinique, Pavillon Georges Heuyer, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France; Sorbonne Université, Inserm CNRS 1135 "NK and T Cell Immunity, Virus and Cancer", Centre d'Immunologie et des Pathologies Infectieuses (CIMI), UPMC UMRS CR7-Inserm U1135-CNRS ERL 8255, faculté de Médecine Sorbonne Université, Site Pitié-Salpêtrière, 91 boulevard de l'Hôpital, 75013 Paris, France
| | - Benjamin Terrier
- Assistance Publique-Hôpitaux de Paris, Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin Paris, Université Paris, France
| | - Jacques Eric Gottenberg
- Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; CNR RESO, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Laboratoire d'Immunopathologie et de Chimie Thérapeutique, Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR3572, Strasbourg, France
| | - Caroline Besson
- Université Paris-Saclay, UVSQ, CESP-INSERM1018, CH de Versailles, 78150, Le Chesnay, France
| | - Sophie Letrou
- Département d'Épidémiologie, Biostatistique et Recherche Clinique Unité de Recherche Clinique Paris Nord APHP, Nord - Université Paris Cité Hôpital Bichat - Claude-Bernard 46 rue Henri Huchard, 75877 Paris Cedex 18, France
| | - Sabrina Kali
- Clinical Research Department, ANRS|Emerging infectious disease, PariSanté Campus, 2 rue d'Oradour-sur-Glane, 75015 Paris, France
| | - Denis Angoulvant
- Service de Cardiologie, CHRU de Tours & EA4245 Transplantation Immunologie et Inflammation, Université de Tours, F37000 Tours, France
| | - Karine Barthélémy
- Unité des Virus Émergents, INSERM-1207, IRD-190, Aix-Marseille University, France
| | - Stéphane Priet
- Unité des Virus Émergents, INSERM-1207, IRD-190, Aix-Marseille University, France
| | - Elif Nurtop
- Unité des Virus Émergents, INSERM-1207, IRD-190, Aix-Marseille University, France
| | | | - Coralie Tardivon
- Department of Epidemiology Biostatistics and Clinical Research, AP-HP, Hôpital Bichat, Paris, France; Centre d'Investigation clinique-Epidémiologie Clinique 1425, Inserm, Hôpital Bichat, Paris, France
| | - Gilles Blancho
- Institut de Transplantation- Urologie - Néphrologie (ITUN) Hôtel Dieu - CHU de Nantes, 30 bd Jean-Monnet, 44093 Nantes, France
| | - Amandine Le Bourgeois
- Service d'hématologie clinique, CHU Nantes, 1 place Alexis Ricordeau, 44000 Nantes, France
| | - Vincent Lévy
- Département de Recherche Clinique, Hôpital Avicenne, APHP, Université Sorbonne Paris Nord and CRESS INSERM U1153, ECSTRRA Team, Paris, France.
| |
Collapse
|
5
|
Launay O, Cachanado M, Luong LB, Ninove L, Lachâtre M, Ghezala IB, Bardou M, Schmidt-Mutter C, Lacombe K, Laine F, Allain JS, Botelho-Nevers E, Tavolacci MP, Chidiac C, Pavese P, Dussol B, Priet S, Deplanque D, Touati A, Curci L, Konate E, Hamouda NB, Besbes A, Nubret E, Capelle F, Berard L, Rousseau A, Tartour E, Simon T, Lamballerie XD, Felten R, SURGERS L. 1954. Immunogenicity against SARS CoV-2 ancestral strain and variants of two new COVID-19 recombinant adjuvanted vaccines compared to BNT162b2 as a third dose following two doses of BNT162b2: a single-blinded multicenter randomized controlled trial. Open Forum Infect Dis 2022. [DOI: 10.1093/ofid/ofac492.1580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Abstract
Background
New adjuvanted recombinant protein vaccines against coronavirus disease 2019 (COVID-19) as heterologous boosters could maximize the benefits of vaccination against SARS CoV-2.
Methods
In this randomized, single-blinded, multicenter trial, adults who had received two doses of Pfizer-BioNTech mRNA vaccine (BNT162b2) 3–7 months before were randomly assigned to receive a boost of BNT162b2, Sanofi/GSK SARS-CoV-2 adjuvanted recombinant protein MV D614 (monovalent parental formulation) or SARS-CoV-2 adjuvanted recombinant protein MV B.1.351 vaccine (monovalent Beta formulation). The primary endpoint was the percentage of subjects with a ≥ 10-fold increase in neutralizing antibody titers for the Wuhan (D614) and B.1.351 (Beta) SARS-CoV-2 viral strains between D0 and D15.
Results
The percentages of participants whose neutralizing antibody titers against the Wuhan (D614) SARS-CoV-2 strain increased by a factor ≥ 10 between Day 0 and Day 15 was 55.3% (95% CI 43.4-66.7) in MV(D614) group (n=76), 76.1% (64.5-85.4) in MV(Beta) group (n=71) and 63.2% (51.3-73.9) in BNT162b2 group (n=76). These percentages were 44.7% (33.3-56.6), 84.5% (74.0-92.0) and 51.3% (39.6-63.0) for the B.1.351 (Beta) viral strain, respectively. Higher neutralizing antibodies rates against Delta and Omicron BA.1 variants were also elicited after Sanofi/GSK MV(Beta) vaccine compared to the other vaccines. Comparable reactogenicity profile was observed the three vaccines. Table 1.Characteristics of patients at inclusion (per-protocol population).Figure 2.Neutralizing antibodies against D614 (wild-type; Wuhan) SARS-CoV-2 and variants Beta, Delta and Omicron BA.1 at D0, D15 and D28 after the boost dose (“post D3”)with Sanofi/GSK-D614, Sanofi/GSK-B.1.351 or BNT162b2 (per-protocol population); dotted line represents the positivity threshold.Figure 4.Rates and grades of severity of solicited adverse events reported from D0 to D7 by participants from the three randomized groups of the safety population (G1, Sanofi/GSK-D614; G2, Sanofi/GSK-B.1.351; G3, BNT162b2) according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (Modified FDA scale/September 2007)
Conclusion
All three vaccines boosted antibodies and neutralizing response after BNT162b2 initial course. Heterologous boosting with the Sanofi/GSK SARS-CoV-2 adjuvanted recombinant protein vaccine B.1.351 (Beta formulation) provided higher neutralizing antibodies response rates against variants, including Omicron BA.1, compared with the mRNA BNT162b2 vaccine.
Disclosures
Odile Launay, MD, PhD, AstraZeneca: Financial|GlaxoSmithKline: Advisor/Consultant|GlaxoSmithKline: Grant/Research Support|Johnson & Johnson: Advisor/Consultant|Johnson & Johnson: Grant/Research Support|MD: Advisor/Consultant|Moderna: Advisor/Consultant|MSD: Data safety monitoring board|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant|Sanofi Pasteur: Grant/Research Support|Sanofi Pasteur: Data safety monitoring board Liem Binh Luong, MD, Pfizer: Advisor/Consultant|Pfizer: Honoraria Karine Lacombe, MD, PhD, Gilead: Advisor/Consultant|Janssen: Grant/Research Support|MSD: Grant/Research Support|ViiV Healthcare: Grant/Research Support Elisabeth Botelho-Nevers, MD, PHD, Janssen: Board Member|Pfizer: Board Member|Sanofi Pasteur: Board Member.
Collapse
Affiliation(s)
- Odile Launay
- Université Paris Cité; Inserm F-CRIN , I-REIVAC; Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France , France
| | - Marine Cachanado
- Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB) , APHP, Hôpital St Antoine, Paris, France, Paris, Ile-de-France , France
| | - Liem Binh Luong
- AP-HP, Hôpital Cochin; Inserm CIC 1417 , Paris , France ; , France, Paris, Ile-de-France , France
- Inserm, F-CRIN, I REIVAC/COVIREIVAC , Paris , France ; , France, Paris, Ile-de-France , France
| | - Laetitia Ninove
- Unité des Virus Emergents, UVE : Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection , 13005, Marseille, France, Marseille, Provence-Alpes-Cote d'Azur , France
| | - Marie Lachâtre
- AP-HP, Hôpital Cochin; Inserm CIC 1417 , Paris , France ; , France, Paris, Ile-de-France , France
- Inserm, F-CRIN, I REIVAC/COVIREIVAC , Paris , France ; , France, Paris, Ile-de-France , France
| | - Inès Ben Ghezala
- Inserm, CIC 1432, Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, University Hospital , Dijon , France ; , France, Dijon, Bourgogne , France
- F-CRIN, I REIVAC/COVIREIVAC , Dijon , France ; , France, Dijon, Bourgogne , France
| | - Marc Bardou
- Inserm, CIC 1432, Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, University Hospital , Dijon , France ; , France, Dijon, Bourgogne , France
- F-CRIN, I REIVAC/COVIREIVAC , Dijon , France ; , France, Dijon, Bourgogne , France
| | - Catherine Schmidt-Mutter
- CIC Inserm 1434, Hôpitaux Universitaires de Strasbourg , France ; , France, Strasbourg, Alsace , France
- F-CRIN, I REIVAC/COVIREIVAC , France ; , France, Strasbourg, Alsace , France
| | - Karine Lacombe
- Sorbonne Inserm UMR-S1136, Hôpital St Antoine , AP-HP, Paris , France ; , France, Paris, Ile-de-France , France
- F-CRIN, I REIVAC/COVIREIVAC , AP-HP, Paris , France ; , France, Paris, Ile-de-France , France
| | - Fabrice Laine
- INSERM, CIC1414 , CHU Rennes, Rennes , France ; , France, Rennes, Bretagne , France
- F-CRIN, I REIVAC/COVIREIVAC , CHU Rennes, Rennes , France ; , France, Rennes, Bretagne , France
| | - Jean-Sébastien Allain
- INSERM, CIC1414 , CHU Rennes, Rennes , France ; , France, Rennes, Bretagne , France
- F-CRIN, I REIVAC/COVIREIVAC , CHU Rennes, Rennes , France ; , France, Rennes, Bretagne , France
| | - Elisabeth Botelho-Nevers
- Service d’infectiologie , CIC1408, Inserm, CHU de Saint-Etienne, 42055 Saint-Etienne , France ; , France, Saint Etienne, Auvergne , France
- F-CRIN, I REIVAC/COVIREIVAC , CIC1408, Inserm, CHU de Saint-Etienne, 42055 Saint-Etienne , France ; , France, Saint Etienne, Auvergne , France
| | - Marie-Pierre Tavolacci
- Normandie Univ , UNIROUEN, U1073, CHU Rouen, and CIC-CRB 1404, F-76000 Rouen , France ; , France, Rouen, Haute-Normandie , France
- F-CRIN, I REIVAC/COVIREIVAC , UNIROUEN, U1073, CHU Rouen, and CIC-CRB 1404, F-76000 Rouen , France ; , France, Rouen, Haute-Normandie , France
| | - Christian Chidiac
- 13. Maladies Infectieuses, GHN Croix Rousse, Hospices Civils de Lyon, UFR de Médecine et Maïeutique Lyon Sud Université Claude Bernard Lyon1, Université de Lyon , CIRI PHE3ID, Inserm U1111 UMR5308 - ENS Lyon; F-CRIN, I REIVAC/COVIREIVAC, France, Lyon, Rhone-Alpes , France
| | - Patricia Pavese
- Maladies infectieuses et tropicales , CHU de Grenoble Alpes , France ; , France, Grenoble, Rhone-Alpes , France
- Inserm, F-CRIN, I REIVAC/COVIREIVAC , CHU de Grenoble Alpes , France ; , France, Grenoble, Rhone-Alpes , France
| | - Bertrand Dussol
- CIC 14-09, INSERM - Aix Marseille Université – Hôpitaux Universitaires de Marseille; Inserm, F-CRIN, I REIVAC/COVIREIVAC , France, Marseille, Provence-Alpes-Cote d'Azur , France
| | - Stéphane Priet
- Unité des Virus Émergents, UVE: Aix Marseille Univ , IRD 190, INSERM 1207, Marseille, France, Marseille, Provence-Alpes-Cote d'Azur , France
| | - Dominique Deplanque
- Univ. Lille, Inserm, CHU Lille, CIC 1403 - Centre d’investigation clinique , F-59000 Lille , France ; , France, Lille, Nord-Pas-de-Calais , France
- F-CRIN, I REIVAC/COVIREIVAC , F-59000 Lille , France ; , France, Lille, Nord-Pas-de-Calais , France
| | - Amel Touati
- Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB) , APHP, Hôpital St Antoine, Paris, France, Paris, Ile-de-France , France
| | - Laureen Curci
- AP-HP, Hôpital Cochin; Inserm CIC 1417 , Paris , France ; , France, Paris, Ile-de-France , France
- Inserm, F-CRIN, I REIVAC/COVIREIVAC , Paris , France ; , France, Paris, Ile-de-France , France
| | - Eleine Konate
- AP-HP, Hôpital Cochin; Inserm CIC 1417 , Paris , France ; , France, Paris, Ile-de-France , France
- Inserm, F-CRIN, I REIVAC/COVIREIVAC , Paris , France ; , France, Paris, Ile-de-France , France
| | - Nadine Ben Hamouda
- Service d’Immunologie Biologique, APHP, Hôpital Européen Georges Pompidou , 75015 Paris , France ; , 75006 Paris, France, Paris, Ile-de-France , France
- PARCC, INSERM U970, Université de Paris , 75015 Paris , France ; , 75006 Paris, France, Paris, Ile-de-France , France
| | - Anissa Besbes
- Service d’Immunologie Biologique, APHP, Hôpital Européen Georges Pompidou , 75015 Paris , France ; , 75006 Paris, France, Paris, Ile-de-France , France
- PARCC, INSERM U970, Université de Paris , 75015 Paris , France ; , 75006 Paris, France, Paris, Ile-de-France , France
| | - Eunice Nubret
- APHP, Direction de la Recherche Clinique et de l’Innovation (DRCI) , Paris, France, Paris, Ile-de-France , France
| | - Florence Capelle
- Département des Essais Cliniques de l’AGEPS, DRCI-APHP , Paris, France, Paris, Ile-de-France , France
| | - Laurence Berard
- Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB) , APHP, Hôpital St Antoine, Paris, France, Paris, Ile-de-France , France
| | - Alexandra Rousseau
- Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB) , APHP, Hôpital St Antoine, Paris, France, Paris, Ile-de-France , France
| | - Eric Tartour
- Service d’Immunologie Biologique, APHP, Hôpital Européen Georges Pompidou , 75015 Paris , France ; , 75006 Paris, France, Paris, Ile-de-France , France
- PARCC, INSERM U970, Université de Paris , 75015 Paris , France ; , 75006 Paris, France, Paris, Ile-de-France , France
| | - Tabassome Simon
- Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB) , APHP, Hôpital St Antoine, Paris, France, Paris, Ile-de-France , France
| | - Xavier De Lamballerie
- Unité des Virus Émergents, UVE: Aix Marseille Univ , IRD 190, INSERM 1207, Marseille, France, Marseille, Provence-Alpes-Cote d'Azur , France
| | - Renaud Felten
- Inserm CIC 1434, CHU Strasbourg, Strasbourg, F-CRIN, I REIVAC/COVIREIVAC , Strasbourg, Alsace , France
| | - Laure SURGERS
- Sorbonne Université, IPLESP Inserm UMR-S1136, Hôpital St Antoine , AP-HP, Paris, France - F-CRIN, I REIVAC/COVIREIVAC, Paris, Ile-de-France , France
| |
Collapse
|
6
|
Launay O, Cachanado M, Luong Nguyen LB, Ninove L, Lachâtre M, Ben Ghezala I, Bardou M, Schmidt-Mutter C, Lacombe K, Laine F, Allain JS, Botelho-Nevers E, Tavolacci MP, Chidiac C, Pavese P, Dussol B, Priet S, Deplanque D, Touati A, Curci L, Konate E, Ben Hamouda N, Besbes A, Nubret E, Capelle F, Berard L, Rousseau A, Tartour E, Simon T, de Lamballerie X. Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. N Engl J Med 2022; 387:374-376. [PMID: 35767474 PMCID: PMC9258749 DOI: 10.1056/nejmc2206711] [Citation(s) in RCA: 35] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Fabrice Laine
- Centre Hospitalier Universitaire (CHU) Rennes, Rennes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Eunice Nubret
- Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | | | | | - Eric Tartour
- Hôpital Européen Georges Pompidou, Paris, France
| | | | | |
Collapse
|
7
|
Luciani L, Inchauste L, Ferraris O, Charrel R, Nougairède A, Piorkowski G, Peyrefitte C, Bertagnoli S, de Lamballerie X, Priet S. Author Correction: A novel and sensitive real-time PCR system for universal detection of poxviruses. Sci Rep 2022; 12:5961. [PMID: 35396370 PMCID: PMC8993887 DOI: 10.1038/s41598-022-09876-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Léa Luciani
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
| | - Lucia Inchauste
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Olivier Ferraris
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.,Centre National de Référence‑Laboratoire Expert Orthopoxvirus, Institut de Recherche Biomédicale Des Armées (IRBA), 91220, Brétigny‑sur‑Orge, France
| | - Rémi Charrel
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Antoine Nougairède
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Géraldine Piorkowski
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Christophe Peyrefitte
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.,Centre National de Référence‑Laboratoire Expert Orthopoxvirus, Institut de Recherche Biomédicale Des Armées (IRBA), 91220, Brétigny‑sur‑Orge, France
| | | | - Xavier de Lamballerie
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Stéphane Priet
- Unité Des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| |
Collapse
|
8
|
Carrat F, de Lamballerie X, Rahib D, Blanché H, Lapidus N, Artaud F, Kab S, Renuy A, Szabo de Edelenyi F, Meyer L, Lydié N, Charles MA, Ancel PY, Jusot F, Rouquette A, Priet S, Saba Villarroel PM, Fourié T, Lusivika-Nzinga C, Nicol J, Legot S, Druesne-Pecollo N, Esseddik Y, Lai C, Gagliolo JM, Deleuze JF, Bajos N, Severi G, Touvier M, Zins M. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. Int J Epidemiol 2021; 50:1458-1472. [PMID: 34293141 PMCID: PMC8344948 DOI: 10.1093/ije/dyab110] [Citation(s) in RCA: 50] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/04/2021] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors. METHODS Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). Estimates were adjusted using sampling weights and post-stratification methods. Multiple imputation was used to infer the cumulative incidence of SARS-CoV-2 infection with adjustments for imperfect tests accuracies. RESULTS The analysis included 14 628 participants, 983 with a positive ELISA-S. The weighted estimates of seropositivity and cumulative incidence were 10.0% [95% confidence interval (CI): 9.1%, 10.9%] and 11.4% (95% CI: 10.1%, 12.8%) in IDF, 9.0% (95% CI: 7.7%, 10.2%) and 9.8% (95% CI: 8.1%, 11.8%) in GE and 3.1% (95% CI: 2.4%, 3.7%) and 2.9% (95% CI: 2.1%, 3.8%) in NA, respectively. Seropositivity was higher in younger participants [odds ratio (OR) = 1.84 (95% CI: 1.79, 6.09) in <40 vs 50-60 years old and OR = 0.56 (95% CI: 0.42, 0.74) in ≥70 vs 50-60 years old)] and when at least one child or adolescent lived in the same household [OR = 1.30 (95% CI: 1.11, 1.53)] and was lower in smokers compared with non-smokers [OR = 0.71 (95% CI: 0.57, 0.89)]. CONCLUSIONS Seropositivity to anti-SARS-CoV-2 antibodies in the French adult population was ≤10% after the first wave. Modifiable and non-modifiable risk factors were identified.
Collapse
Affiliation(s)
- Fabrice Carrat
- Sorbonne Université, Inserm, Institut Pierre-Louis d’Epidémiologie et de Santé Publique, Paris, France
- Département de Santé Publique, APHP.Sorbonne Université, Paris, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France
| | | | - Hélène Blanché
- Fondation Jean Dausset-CEPH (Centre d’Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France
| | - Nathanael Lapidus
- Sorbonne Université, Inserm, Institut Pierre-Louis d’Epidémiologie et de Santé Publique, Paris, France
- Département de Santé Publique, APHP.Sorbonne Université, Paris, France
| | - Fanny Artaud
- CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France
| | - Sofiane Kab
- Paris University, Paris, France
- Paris-Saclay University, Inserm UMS 11, Villejuif, France
| | - Adeline Renuy
- Paris University, Paris, France
- Paris-Saclay University, Inserm UMS 11, Villejuif, France
| | - Fabien Szabo de Edelenyi
- Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France
| | - Laurence Meyer
- Université Paris-Saclay, Inserm, CESP U1018, Le Kremlin Bicêtre, France
- Service de Santé Publique, APHP.Paris Saclay, Le Kremlin Bicêtre, France
| | | | | | - Pierre-Yves Ancel
- Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité, Inserm U1153, Paris Descartes University, Paris, France
- Clinical Research Unit, Center for Clinical Investigation P1419, Cochin Broca Hôtel-Dieu Hospital, Paris, France
| | - Florence Jusot
- Université Paris-Dauphine, PSL-Research University, LEDa, Paris, France
| | - Alexandra Rouquette
- Université Paris-Saclay, Inserm, CESP U1018, Le Kremlin Bicêtre, France
- Service de Santé Publique, APHP.Paris Saclay, Le Kremlin Bicêtre, France
| | - Stéphane Priet
- Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France
| | - Paola Mariela Saba Villarroel
- Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France
| | - Toscane Fourié
- Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France
| | - Clovis Lusivika-Nzinga
- Sorbonne Université, Inserm, Institut Pierre-Louis d’Epidémiologie et de Santé Publique, Paris, France
| | - Jérôme Nicol
- Sorbonne Université, Inserm, Institut Pierre-Louis d’Epidémiologie et de Santé Publique, Paris, France
| | - Stephane Legot
- Paris University, Paris, France
- Paris-Saclay University, Inserm UMS 11, Villejuif, France
| | - Nathalie Druesne-Pecollo
- Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France
| | - Younes Esseddik
- Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France
| | - Cindy Lai
- Institut de Santé Publique, Pôle Recherche Clinique, Institut National de la Santé et de la Recherche Médicale, Paris, France
| | | | - Jean-François Deleuze
- Fondation Jean Dausset-CEPH (Centre d’Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France
| | | | - Gianluca Severi
- CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France
- Department of Statistics, Computer Science and Applications, University of Florence, Florence, Italy
| | - Mathilde Touvier
- Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France
| | - Marie Zins
- Paris University, Paris, France
- Paris-Saclay University, Inserm UMS 11, Villejuif, France
| | | |
Collapse
|
9
|
Carrat F, de Lamballerie X, Rahib D, Blanché H, Lapidus N, Artaud F, Kab S, Renuy A, Szabo de Edelenyi F, Meyer L, Lydié N, Charles MA, Ancel PY, Jusot F, Rouquette A, Priet S, Saba Villarroel PM, Fourié T, Lusivika-Nzinga C, Nicol J, Legot S, Druesne-Pecollo N, Esseddik Y, Lai C, Gagliolo JM, Deleuze JF, Bajos N, Severi G, Touvier M, Zins M. Corrigendum to: Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. Int J Epidemiol 2021; 50:1755. [PMID: 34453524 PMCID: PMC8787412 DOI: 10.1093/ije/dyab173] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
10
|
Luciani L, Inchauste L, Ferraris O, Charrel R, Nougairède A, Piorkowski G, Peyrefitte C, Bertagnoli S, de Lamballerie X, Priet S. A novel and sensitive real-time PCR system for universal detection of poxviruses. Sci Rep 2021; 11:1798. [PMID: 33469067 PMCID: PMC7815923 DOI: 10.1038/s41598-021-81376-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Accepted: 12/22/2020] [Indexed: 11/16/2022] Open
Abstract
Success in smallpox eradication was enabled by the absence of non-human reservoir for smallpox virus. However, other poxviruses with a wider host spectrum can infect humans and represent a potential health threat to humans, highlighted by a progressively increasing number of infections by (re)emerging poxviruses, requiring new improved diagnostic and epidemiological tools. We describe here a real-time PCR assay targeting a highly conserved region of the poxvirus genome, thus allowing a pan-Poxvirus detection (Chordopoxvirinae and Entomopoxvirinae). This system is specific (99.8% for vertebrate samples and 99.7% for arthropods samples), sensitive (100% for vertebrate samples and 86.3% for arthropods samples) and presents low limit of detection (< 1000 DNA copies/reaction). In addition, this system could be also valuable for virus discovery and epidemiological projects.
Collapse
Affiliation(s)
- Léa Luciani
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
| | - Lucia Inchauste
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Olivier Ferraris
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.,Centre National de Référence-Laboratoire Expert Orthopoxvirus, Institut de Recherche Biomédicale Des Armées (IRBA), 91220, Brétigny-sur-Orge, France
| | - Rémi Charrel
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Antoine Nougairède
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Géraldine Piorkowski
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Christophe Peyrefitte
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.,Centre National de Référence-Laboratoire Expert Orthopoxvirus, Institut de Recherche Biomédicale Des Armées (IRBA), 91220, Brétigny-sur-Orge, France
| | | | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France
| |
Collapse
|
11
|
Velier M, Priet S, Appay R, Atieh T, Lepidi H, Kaplanski G, Jarrot PA, Koubi M, Costello R, Dignat-George F, de Lamballerie X, Tichadou A, Arcani R, Couderc AL, Touati J, Varoquaux A, Berda-Haddad Y, Venton G. Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2021; 21:e503-e505. [PMID: 33563581 PMCID: PMC7832621 DOI: 10.1016/j.clml.2021.01.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Accepted: 01/09/2021] [Indexed: 02/08/2023]
Affiliation(s)
- Mélanie Velier
- Laboratory of Hematology and Vascular biology, Conception University Hospital, Marseille, France; Center for Cardiovascular and Nutrition Research (C2VN), INRA 1260, INSERM 1263, Aix-Marseille University, Marseille, France.
| | - Stéphane Priet
- Unité des Virus Émergents (UVE), IRD 190, Inserm 1207, Aix-Marseille University, Marseille, France
| | - Romain Appay
- Pathology and Neuropathology Department, La Timone University Hospital, Marseille, France; CNRS, INP, Inst Neurophysiopathol, Aix-Marseille University, Marseille, France
| | - Thérèse Atieh
- Unité des Virus Émergents (UVE), IRD 190, Inserm 1207, Aix-Marseille University, Marseille, France
| | - Hubert Lepidi
- Pathology and Neuropathology Department, La Timone University Hospital, Marseille, France
| | - Gilles Kaplanski
- Center for Cardiovascular and Nutrition Research (C2VN), INRA 1260, INSERM 1263, Aix-Marseille University, Marseille, France; Internal Medical and Clinical Immunology, Conception University Hospital, Marseille, France
| | - Pierre André Jarrot
- Center for Cardiovascular and Nutrition Research (C2VN), INRA 1260, INSERM 1263, Aix-Marseille University, Marseille, France; Internal Medical and Clinical Immunology, Conception University Hospital, Marseille, France
| | - Marie Koubi
- Internal Medical and Clinical Immunology, Conception University Hospital, Marseille, France
| | - Régis Costello
- Hematology and Cellular Therapy Department, Conception University Hospital, Marseille, France; TAGC, INSERM, UMR1090, Aix-Marseille University, Marseille, France
| | - Françoise Dignat-George
- Laboratory of Hematology and Vascular biology, Conception University Hospital, Marseille, France; Center for Cardiovascular and Nutrition Research (C2VN), INRA 1260, INSERM 1263, Aix-Marseille University, Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE), IRD 190, Inserm 1207, Aix-Marseille University, Marseille, France
| | - Antoine Tichadou
- Hematology and Cellular Therapy Department, Conception University Hospital, Marseille, France; TAGC, INSERM, UMR1090, Aix-Marseille University, Marseille, France; SMARTc Unit, Pharmacokinetics Laboratory, UMR_911 CRO2 Aix-Marseille University, Marseille, France
| | - Robin Arcani
- Center for Cardiovascular and Nutrition Research (C2VN), INRA 1260, INSERM 1263, Aix-Marseille University, Marseille, France; Internal Medicine, Geriatrics and Therapeutics Department and Coordination Unit for Geriatric Oncology (UCOG), La Timone University Hospital, Marseille, France
| | - Anne Laure Couderc
- Internal Medicine, Geriatrics and Therapeutics Department and Coordination Unit for Geriatric Oncology (UCOG), La Timone University Hospital, Marseille, France; CNRS, EFS, ADES, Aix-Marseille University, Marseille, France
| | - Julian Touati
- Department of Medical Imaging, Conception University Hospital, Marseille, France; Center for Magnetic Resonance in Biology and Medicine, UMR 7339, La Timone University Hospital, Aix-Marseille University, Marseille, France
| | - Arthur Varoquaux
- Department of Medical Imaging, Conception University Hospital, Marseille, France; Center for Magnetic Resonance in Biology and Medicine, UMR 7339, La Timone University Hospital, Aix-Marseille University, Marseille, France
| | - Yaël Berda-Haddad
- Laboratory of Hematology and Vascular biology, Conception University Hospital, Marseille, France
| | - Geoffroy Venton
- Hematology and Cellular Therapy Department, Conception University Hospital, Marseille, France; TAGC, INSERM, UMR1090, Aix-Marseille University, Marseille, France; SMARTc Unit, Pharmacokinetics Laboratory, UMR_911 CRO2 Aix-Marseille University, Marseille, France
| |
Collapse
|
12
|
Capai L, Hozé N, Chiaroni J, Gross S, Djoudi R, Charrel R, Izopet J, Bosseur F, Priet S, Cauchemez S, de Lamballerie X, Falchi A, Gallian P. Seroprevalence of hepatitis E virus among blood donors on Corsica, France, 2017. ACTA ACUST UNITED AC 2020; 25. [PMID: 32046820 PMCID: PMC7014670 DOI: 10.2807/1560-7917.es.2020.25.5.1900336] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Background Hepatitis E virus (HEV) is an emerging zoonotic pathogen and an important cause of acute viral hepatitis in European countries. Corsica Island has been previously identified as a hyperendemic area for HEV. Aim Our aim was to characterise the prevalence and titres of IgG antibodies to HEV among blood donors on Corsica and establish a model of the annual force of infection. Methods Between September 2017 and January 2018, 2,705 blood donations were tested for anti-HEV IgG using the Wantai HEV IgG enzyme immunoassay. Results The overall seroprevalence was 56.1%. In multivariate analysis, seroprevalence was higher in men than in women (60.0% vs 52.2%; p < 0.01), increased with age and was significantly higher among donors born on Corsica (60.6% vs 53.2%; p < 0.01). No significant difference was observed between the five districts of the island. IgG anti-HEV titres were mostly low (70% of positive donors had titres < 3 IU/mL). In Corsican natives, increasing seroprevalence by age could be explained by models capturing a loss of immunity (annual probability of infection: 4.5%; duration of immunity: 55 years) or by age-specific probabilities of infection (3.8% for children, 1.3% for adults). Conclusion We confirmed the high HEV seroprevalence on Corsica and identified three aspects that should be further explored: (i) the epidemiology in those younger than 18 years, (ii) common sources of contamination, in particular drinking water, that may explain the wide exposure of the population, and (iii) the actual protection afforded by the low IgG titres observed and the potential susceptibility to secondary HEV infection.
Collapse
Affiliation(s)
- Lisandru Capai
- EA 7310, Laboratoire de Virologie, Université de Corse, Corte, France
| | - Nathanaël Hozé
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
| | - Jacques Chiaroni
- Etablissement Français du Sang Provence alpes Côte d'Azur et Corse, Marseille, France
| | - Sylvie Gross
- Etablissement Français du Sang, 93210, La Plaine-Saint-Denis, France
| | - Rachid Djoudi
- Etablissement Français du Sang, 93210, La Plaine-Saint-Denis, France
| | - Rémi Charrel
- Unité des Virus Émergents (UVE): Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, Marseille, France
| | - Jacques Izopet
- Institut National de la Santé et de la Recherche Médicale Unité 1043, Université Toulouse III, Toulouse, France.,Laboratoire de Virologie, Institut Fédératif de Biologie, Centre Hospitalier et Universitaire, Toulouse, France
| | - Frédéric Bosseur
- Sciences Pour l'Environnement - UMR CNRS 6134 Université de Corse, Corte, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE): Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, Marseille, France
| | - Simon Cauchemez
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE): Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, Marseille, France
| | - Alessandra Falchi
- EA 7310, Laboratoire de Virologie, Université de Corse, Corte, France
| | - Pierre Gallian
- Unité des Virus Émergents (UVE): Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, Marseille, France.,Etablissement Français du Sang, 93210, La Plaine-Saint-Denis, France.,Etablissement Français du Sang Provence alpes Côte d'Azur et Corse, Marseille, France
| |
Collapse
|
13
|
Fichez J, Soulie C, Le Corre L, Sayon S, Priet S, Alvarez K, Delelis O, Gizzi P, Prestat G, Gravier-Pelletier C, Marcelin AG, Calvez V, Busca P. Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1 H-pyrazole-5-carboxylate as an HIV-1 replication inhibitor. RSC Med Chem 2020; 11:577-582. [PMID: 33479659 PMCID: PMC7593888 DOI: 10.1039/d0md00025f] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Accepted: 03/14/2020] [Indexed: 11/21/2022] Open
Abstract
Inspired by the antiviral activity of known pyrazole-based HIV inhibitors, we screened our in-house library of pyrazole-based compounds to evaluate their in cellulo activity against HIV-1 replication. Two hits with very similar structures appeared from single and multiple-round infection assays to be non-toxic and active in a dose-dependent manner. Chemical expansion of their series allowed an in-depth and consistent structure-activity-relationship study (SAR) to be built. Further ADME evaluation led to the selection of 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate with an advantageous pharmacokinetic profile. Finally, examination of its mode of action revealed that this compound does not belong to the three main classes of anti-HIV drugs, a feature of prime interest in the context of viral resistance.
Collapse
Affiliation(s)
- Jeanne Fichez
- LCBPT , UMR CNRS 8601 , Université de Paris , Paris , France .
| | - Cathia Soulie
- Laboratoire de Virologie-CERVI , UMR S 1136 , Hôpital Pitié Salpêtrière - Sorbonne Université , Paris , France
| | | | - Sophie Sayon
- Laboratoire de Virologie-CERVI , UMR S 1136 , Hôpital Pitié Salpêtrière - Sorbonne Université , Paris , France
| | - Stéphane Priet
- Aix-Marseille Univ , Laboratoire AFMB , UMR CNRS 7257 , Marseille , France
- UMR EPV , Université Aix-Marseille - IRD 190 - INSERM 1207 - EHESP , Marseille , France
| | - Karine Alvarez
- Aix-Marseille Univ , Laboratoire AFMB , UMR CNRS 7257 , Marseille , France
| | | | - Patrick Gizzi
- PCBIS , UMS CNRS 3286 , ESBS - Université de Strasbourg , Illkirch , France
| | | | | | - Anne-Geneviève Marcelin
- Laboratoire de Virologie-CERVI , UMR S 1136 , Hôpital Pitié Salpêtrière - Sorbonne Université , Paris , France
| | - Vincent Calvez
- Laboratoire de Virologie-CERVI , UMR S 1136 , Hôpital Pitié Salpêtrière - Sorbonne Université , Paris , France
| | - Patricia Busca
- LCBPT , UMR CNRS 8601 , Université de Paris , Paris , France .
| |
Collapse
|
14
|
Nurtop E, Moyen N, Dzia-Lepfoundzou A, Dimi Y, Ninove L, Drexler JF, Gallian P, de Lamballerie X, Priet S. A Report of Zika Virus Seroprevalence in Republic of the Congo. Vector Borne Zoonotic Dis 2019; 20:40-42. [PMID: 31448988 DOI: 10.1089/vbz.2019.2466] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Zika virus (ZIKV) is an arthropod-borne RNA virus (arbovirus), belonging to the Spondweni serogroup. ZIKV was first described in Africa in 1947 and remained sporadic until Micronesia outbreak in 2007, which was followed by outbreaks in the Pacific Islands, Latin America, and the Caribbean. Subsequent to the epidemics, ZIKV revealed its severity as virus was sexually transmissible, and it was associated with serious fetal and neurological complications. ZIKV originated from Africa; however, little is known about the epidemiology of the virus in African populations. Following a recent study in Cameroon that evidenced low ZIKV epidemiology associated with a presumptive (peri-)sylvatic transmission, we performed a seroepidemiological study in Republic of the Congo, neighbor of Cameroon. To accomplish this, 386 serum specimens from volunteer blood donors collected in 2011 from rural and urban areas of Republic of the Congo were tested with ZIKV-specific methodology; primary screening with anti-NS1 ZIKV IgG ELISA followed by confirmation with cytopathic effect (CPE)-based virus neutralization test (VNT). ZIKV seropositivity was determined as low as 1.8%, varying slightly between urban and rural areas (1.7% and 3.6%). These results demonstrate that the majority of the population of Republic of the Congo is immunologically naïve against ZIKV with a presumptive (peri-)sylvatic transmission cycle, which emphasizes the importance of surveillance studies in Africa.
Collapse
Affiliation(s)
- Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | - Nanikaly Moyen
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | | | - Yannick Dimi
- Centre National de Transfusion Sanguine, Brazzaville, Republic of the Congo
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | - Jan Felix Drexler
- Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.,Laboratoire de Virologie, Établissement Français du Sang Provence-Alpes Côte-d'Azur et Corse (EFS), Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| |
Collapse
|
15
|
Nurtop E, Villarroel PMS, Pastorino B, Ninove L, Drexler JF, Roca Y, Gake B, Dubot-Peres A, Grard G, Peyrefitte C, Priet S, de Lamballerie X, Gallian P. Correction to: Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J 2019; 16:12. [PMID: 30654811 PMCID: PMC6337804 DOI: 10.1186/s12985-019-1118-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 01/08/2019] [Indexed: 11/26/2022] Open
Affiliation(s)
- Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.
| | - Paola Mariela Saba Villarroel
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Boris Pastorino
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Jan Felix Drexler
- Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Yelin Roca
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Bouba Gake
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,Centre Pasteur du Cameroun, Yaoundé, Cameroon
| | - Audrey Dubot-Peres
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Gilda Grard
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Christophe Peyrefitte
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207- IHU Méditerranée Infection), Marseille, France.,Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS), Marseille, France
| |
Collapse
|
16
|
Nurtop E, Villarroel PMS, Pastorino B, Ninove L, Drexler JF, Roca Y, Gake B, Dubot-Peres A, Grard G, Peyrefitte C, Priet S, de Lamballerie X, Gallian P. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J 2018; 15:192. [PMID: 30587193 PMCID: PMC6307276 DOI: 10.1186/s12985-018-1105-5] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 12/04/2018] [Indexed: 12/21/2022] Open
Abstract
Here we propose a strategy allowing implementing efficient and practicable large-scale seroepidemiological studies for Zika Virus (ZIKV). It combines screening by a commercial NS1 protein-based Zika IgG ELISA, and confirmation by a cytopathic effect-based virus neutralization test (CPE-based VNT). In post-epidemic samples from Martinique Island blood donors (a population with a dengue seroprevalence above 90%), this strategy allowed reaching specificity and sensitivity values over 98%. The CPE-based VNT consists of recording CPE directly under the optical microscope, which is easy to identify with ZIKV strain H/PF/2013 at day 5 pi. Overall, considered that CPE-based VNT is cost effective and widely automatable, the NS1 protein-based Zika IgG ELISA+CPE-based VNT combination strategy represents a convenient tool to expedite ZIKV seroprevalence studies.
Collapse
Affiliation(s)
- Elif Nurtop
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Paola Mariela Saba Villarroel
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Boris Pastorino
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Laetitia Ninove
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Jan-Felix Drexler
- Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Yelin Roca
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Bouba Gake
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- Centre Pasteur du Cameroun, Yaoundé, Cameroon
| | - Audrey Dubot-Peres
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Gilda Grard
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Christophe Peyrefitte
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Stéphane Priet
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
| | - Pierre Gallian
- Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France
- Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS), Marseille, France
| |
Collapse
|
17
|
Saba Villarroel PM, Nurtop E, Pastorino B, Roca Y, Drexler JF, Gallian P, Jaenisch T, Leparc-Goffart I, Priet S, Ninove L, de Lamballerie X. Zika virus epidemiology in Bolivia: A seroprevalence study in volunteer blood donors. PLoS Negl Trop Dis 2018. [PMID: 29513667 PMCID: PMC5858838 DOI: 10.1371/journal.pntd.0006239] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background Zika virus (ZIKV), was widely reported in Latin America and has been associated with neuropathologies, as microcephaly, but only few seroprevalence studies have been published to date. Our objective was to determine the seroprevalence amongst Bolivian blood donors and estimate the future potential circulation of the virus. Methodology A ZIKV seroprevalence study was conducted between December 2016 and April 2017 in 814 asymptomatic Bolivian volunteer blood donors residing in various eco-environments corresponding to contrasting entomological activities. It was based on detection of IgG to ZIKV using NS1 ELISA screening, followed by a seroneutralisation test in case of positive or equivocal ELISA result. Conclusions/Significance Analysis revealed that ZIKV circulation occurred in tropical areas (Beni: 39%; Santa Cruz de la Sierra: 21.5%) but not in highlands (~0% in Cochabamba, La Paz, Tarija). It was modulated by Aedes aegypti activity and the virus spread was not limited by previous immunity to dengue. Cases were geo-localised in a wide range of urban areas in Santa Cruz and Trinidad. No differences in seroprevalence related to gender or age-groups could be identified. It is concluded that ZIKV has been intensely circulating in the Beni region and has still a significant potential for propagating in the area of Santa Cruz. Zika virus (ZIKV) is a virus of African origin, transmitted by Aedes mosquitoes, and related to dengue and yellow fever virus. It was originally believed to be responsible for a mild febrile illness in Africa and South-east Asia. However, in recent years, ZIKV has been responsible for outbreaks in the Pacific Islands before massively spreading in Latin America and the Caribbean. On this occasion, ZIKV has unexpectedly been associated with non-vector transmission (i.e., sexual and mother-to-foetus transmission) and with severe complications such as foetal abnormalities (e.g. microcephaly) and Guillain-Barré syndromes. Little is known about the actual proportion of the populations infected by ZIKV in Latin America. Here, we report a seroprevalence data in this region, after studying 814 asymptomatic Bolivian volunteer blood donors residing in various eco-environments corresponding to contrasting entomological activities. We conclude that ZIKV has been circulating in Bolivian tropical areas but not in highlands, and that the epidemic has not been limited by previous immunity against dengue. Specific attention should be paid to the region of Santa Cruz, where the seroprevalence is still limited, but the density of Aedes aegypti populations makes plausible further spreading of the disease.
Collapse
Affiliation(s)
- Paola Mariela Saba Villarroel
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
- * E-mail:
| | - Elif Nurtop
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| | - Boris Pastorino
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| | - Yelin Roca
- Virología II, Centro Nacional de Enfermedades Tropicales (CENETROP), Santa Cruz de la Sierra, Bolivia
| | - Jan Felix Drexler
- German Centre for Infection Research (DZIF) Charité—Universitätsmedizin Berlin, Berlin, Germany
- Institute of Virology, Charité—Universitätsmedizin Berlin, Berlin, Germany
| | - Pierre Gallian
- Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS), Marseille, France
| | - Thomas Jaenisch
- Department for Infectious Diseases (Section Clinical Tropical Medicine), Heidelberg University Hospital, Heidelberg, Germany
| | - Isabelle Leparc-Goffart
- National Reference Centre for Arboviruses, French Armed Forces Biomedical Research Institute, Marseille, France
| | - Stéphane Priet
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| | - Laetitia Ninove
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| | - Xavier de Lamballerie
- UMR EPV Émergence des Pathologies Virales, Aix-Marseille University—IRD 190—Inserm 1207 –EHESP–IHU Méditerranée Infection, Marseille, France
| |
Collapse
|
18
|
Laux WH, Priet S, Alvarez K, Peyrottes S, Périgaud C. Synthesis and substrate properties towards HIV-1 reverse transcriptase of new diphosphate analogues of 9-[(2-phosphonomethoxy)ethyl]adenine. Antivir Chem Chemother 2018; 26:2040206618757636. [PMID: 29436843 PMCID: PMC5890543 DOI: 10.1177/2040206618757636] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Background The replacement of β,γ-pyrophosphate by β,γ-phosphonate moieties within the triphosphate chain of 5′-triphosphate nucleoside analogues was previously studied for various antiviral nucleoside analogues such as AZT and 2′,3′-dideoxynucleosides. Thus, it has been shown that these chemical modifications could preserve, in some cases, the terminating substrate properties of the triphosphate analogue for HIV-RT. Herein, we aimed to study such 5′-triphosphate mimics based on the scaffold of the well-known antiviral agent 9-[(2-phosphonomethoxy)ethyl]adenine (PMEA, Adefovir). Methods Synthesis involved coupling of a morpholidate derivative of PMEA with appropriate pyrophosphoryl analogues. The relative efficiencies of incorporation of the studied diphosphate phosphonates were measured using subtype B WT HIV-1 RT in an in vitro susceptibility assay, in comparison to the parent nucleotide analogue (PMEApp). Results Searching for nucleoside 5′-triphosphate mimics, we have synthesized and studied a series of diphosphate analogues of PMEA bearing non hydrolysable bonds between the and phosphorus atoms. We also examined their relative inhibitory capacity towards HIV-1 reverse transcriptase in comparison to the parent nucleotide analogue (PMEApp). Only one of them appeared as a weak inhibitor (IC50 = 403.0 ± 75.5 µM) and proved to be less effective than PMEApp (IC50 = 6.4 ± 0.8 µM). Conclusion PMEA diphosphoryl derivatives were designed as potential substrates and/or inhibitors of various viral polymerases. These modifications dramatically affect their ability to inhibit HIV-RT.
Collapse
Affiliation(s)
- Wolfgang Hg Laux
- 1 131825 Institut des Biomolécules Max Mousseron (IBMM) , UMR 5247 CNRS, Univ. Montpellier, ENSCM, Campus Triolet, Montpellier, Cedex, France
| | - Stéphane Priet
- 2 Laboratoire AFMB, AMU, CNRS, UMR 7257, Groupe ''Chimie Médicinale Antivirale'', Marseille, Cedex, France
| | - Karine Alvarez
- 2 Laboratoire AFMB, AMU, CNRS, UMR 7257, Groupe ''Chimie Médicinale Antivirale'', Marseille, Cedex, France
| | - Suzanne Peyrottes
- 1 131825 Institut des Biomolécules Max Mousseron (IBMM) , UMR 5247 CNRS, Univ. Montpellier, ENSCM, Campus Triolet, Montpellier, Cedex, France
| | - Christian Périgaud
- 1 131825 Institut des Biomolécules Max Mousseron (IBMM) , UMR 5247 CNRS, Univ. Montpellier, ENSCM, Campus Triolet, Montpellier, Cedex, France
| |
Collapse
|
19
|
Abstract
Toscana virus (TOSV) is an arthropod-borne phlebovirus within the family Phenuiviridae in the order Bunyavirales. It seems to be an important agent of human meningoencephalitis in the warm season in the Mediterranean area. Because the polymerase of Bunyavirales lacks a capping activity, it cleaves short-capped RNA leaders derived from the host cell, and uses them to initiate viral mRNA synthesis. To determine the size and nucleotide composition of the host-derived RNA leaders, and to elucidate the first steps of TOSV transcription initiation, we performed a high-throughput sequencing of the 5' end of TOSV mRNAs in infected cells at different times post-infection. Our results indicated that the viral polymerase cleaved the host-capped RNA leaders within a window of 11-16 nucleotides. A single population of cellular mRNAs could be cleaved at different sites to prime the synthesis of several viral mRNA species. The majority of the mRNA resulted from direct priming, but we observed mRNAs resulting from several rounds of prime-and-realign events. Our data suggest that the different rounds of the prime-and-realign mechanism result from the blocking of the template strand in a static position in the active site, leading to the slippage of the nascent strand by two nucleotides when the growing duplex is sorted out from the active site. To minimize this rate-limiting step, TOSV polymerase cleaves preferentially capped RNA leaders after GC, so as to greatly reduce the number of cycles of priming and realignment, and facilitate the separation of the growing duplex.
Collapse
Affiliation(s)
- Abdennour Amroun
- UMR 'Emergence des Pathologies Virales' (EPV: Aix-Marseille Université - IRD 190 - Inserm 1207 - EHESP - IHU Méditerranée Infection), Marseille, France
| | - Stéphane Priet
- UMR 'Emergence des Pathologies Virales' (EPV: Aix-Marseille Université - IRD 190 - Inserm 1207 - EHESP - IHU Méditerranée Infection), Marseille, France
| | - Gilles Querat
- UMR 'Emergence des Pathologies Virales' (EPV: Aix-Marseille Université - IRD 190 - Inserm 1207 - EHESP - IHU Méditerranée Infection), Marseille, France
| |
Collapse
|
20
|
Abstract
Bunyaviridae family is the largest and most diverse family of RNA viruses. It has more than 350 members divided into five genera: Orthobunyavirus, Phlebovirus, Nairovirus, Hantavirus, and Tospovirus. They are present in the five continents, causing recurrent epidemics, epizootics, and considerable agricultural loss. The genome of bunyaviruses is divided into three segments of negative single-stranded RNA according to their relative size: L (Large), M (Medium) and S (Small) segment. Bunyaviridae RNA-dependent RNA polymerase (RdRp) is encoded by the L segment, and is in charge of the replication and transcription of the viral RNA in the cytoplasm of the infected cell. Viral RdRps share a characteristic right hand-like structure with three subdomains: finger, palm, and thumb subdomains that define the formation of the catalytic cavity. In addition to the N-terminal endonuclease domain, eight conserved motifs (A-H) have been identified in the RdRp of Bunyaviridae. In this review, we have summarized the recent insights from the structural and functional studies of RdRp to understand the roles of different motifs shared by RdRps, the mechanism of viral RNA replication, genome segment packaging by the nucleoprotein, cap-snatching, mRNA transcription, and other RNA mechanisms of bunyaviruses.
Collapse
Affiliation(s)
- Abdennour Amroun
- a Faculté de Médecine , UMR "Emergence des Pathologies Virales" (Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP), Fondation IHU Méditerranée Infection, APHM Public Hospitals of Marseille , Marseille , France
| | - Stéphane Priet
- a Faculté de Médecine , UMR "Emergence des Pathologies Virales" (Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP), Fondation IHU Méditerranée Infection, APHM Public Hospitals of Marseille , Marseille , France
| | - Xavier de Lamballerie
- a Faculté de Médecine , UMR "Emergence des Pathologies Virales" (Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP), Fondation IHU Méditerranée Infection, APHM Public Hospitals of Marseille , Marseille , France
| | - Gilles Quérat
- a Faculté de Médecine , UMR "Emergence des Pathologies Virales" (Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP), Fondation IHU Méditerranée Infection, APHM Public Hospitals of Marseille , Marseille , France
| |
Collapse
|
21
|
Raux B, Voitovich Y, Derviaux C, Lugari A, Rebuffet E, Milhas S, Priet S, Roux T, Trinquet E, Guillemot JC, Knapp S, Brunel JM, Fedorov AY, Collette Y, Roche P, Betzi S, Combes S, Morelli X. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins. J Med Chem 2016; 59:1634-41. [PMID: 26735842 DOI: 10.1021/acs.jmedchem.5b01708] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A midthroughput screening follow-up program targeting the first bromodomain of the human BRD4 protein, BRD4(BD1), identified an acetylated-mimic xanthine derivative inhibitor. This compound binds with an affinity in the low micromolar range yet exerts suitable unexpected selectivity in vitro against the other members of the bromodomain and extra-terminal domain (BET) family. A structure-based program pinpointed a role of the ZA loop, paving the way for the development of potent and selective BET-BRDi probes.
Collapse
Affiliation(s)
- Brigitt Raux
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Yuliia Voitovich
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France.,Department of Organic Chemistry, Lobachevsky State University of Nizhni Novgorod , Gagarina av. 23, Nizhni Novgorod 603950, Russia
| | - Carine Derviaux
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Adrien Lugari
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Etienne Rebuffet
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Sabine Milhas
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France.,Screening Platform AD2P, CNRS, AFMB UMR 7257, Aix-Marseille Université , 13288 Marseille, France
| | - Stéphane Priet
- Screening Platform AD2P, CNRS, AFMB UMR 7257, Aix-Marseille Université , 13288 Marseille, France
| | - Thomas Roux
- Cisbio Bioassays, R&D , Parc Marcel Boiteux, BP 84175, 30200 Codolet, France
| | - Eric Trinquet
- Cisbio Bioassays, R&D , Parc Marcel Boiteux, BP 84175, 30200 Codolet, France
| | - Jean-Claude Guillemot
- Screening Platform AD2P, CNRS, AFMB UMR 7257, Aix-Marseille Université , 13288 Marseille, France
| | - Stefan Knapp
- Target Discovery Institute, University of Oxford , NDM Research Building, Roosevelt Drive, Oxford OX3 7FZ, U.K.,Structural Genomics Consortium, University of Oxford , Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, U.K.,Goethe-University , Institute for Pharmaceutical Chemistry and Buchmann Institute for Life Science, Campus Riedberg, Max-von Laue Str. 9, 60438 Frankfurt am Main, Germany
| | - Jean-Michel Brunel
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Alexey Yu Fedorov
- Department of Organic Chemistry, Lobachevsky State University of Nizhni Novgorod , Gagarina av. 23, Nizhni Novgorod 603950, Russia
| | - Yves Collette
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Philippe Roche
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Stéphane Betzi
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Sébastien Combes
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| | - Xavier Morelli
- Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 7258; INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105 , 13273 Marseille, France
| |
Collapse
|
22
|
Potisopon S, Priet S, Collet A, Decroly E, Canard B, Selisko B. The methyltransferase domain of dengue virus protein NS5 ensures efficient RNA synthesis initiation and elongation by the polymerase domain. Nucleic Acids Res 2015; 44:2974. [PMID: 26578566 PMCID: PMC4824071 DOI: 10.1093/nar/gkv1294] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- Supanee Potisopon
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Stéphane Priet
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Axelle Collet
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Etienne Decroly
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Bruno Canard
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Barbara Selisko
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| |
Collapse
|
23
|
Priet S, Lartigue A, Debart F, Claverie JM, Abergel C. mRNA maturation in giant viruses: variation on a theme. Nucleic Acids Res 2015; 43:3776-88. [PMID: 25779049 PMCID: PMC4402537 DOI: 10.1093/nar/gkv224] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Accepted: 03/04/2015] [Indexed: 12/02/2022] Open
Abstract
Giant viruses from the Mimiviridae family replicate entirely in their host cytoplasm where their genes are transcribed by a viral transcription apparatus. mRNA polyadenylation uniquely occurs at hairpin-forming palindromic sequences terminating viral transcripts. Here we show that a conserved gene cluster both encode the enzyme responsible for the hairpin cleavage and the viral polyA polymerases (vPAP). Unexpectedly, the vPAPs are homodimeric and uniquely self-processive. The vPAP backbone structures exhibit a symmetrical architecture with two subdomains sharing a nucleotidyltransferase topology, suggesting that vPAPs originate from an ancestral duplication. A Poxvirus processivity factor homologue encoded by Megavirus chilensis displays a conserved 5′-GpppA 2′O methyltransferase activity but is also able to internally methylate the mRNAs’ polyA tails. These findings elucidate how the arm wrestling between hosts and their viruses to access the translation machinery is taking place in Mimiviridae.
Collapse
Affiliation(s)
- Stéphane Priet
- Architecture et Fonction des Macromolécules Biologiques, CNRS UMR 7257, Aix-Marseille Université, 163 Avenue de Luminy, Case 932, 13288 Marseille cedex 9, France
| | - Audrey Lartigue
- Structural and Genomic Information Laboratory, UMR 7256 (IMM FR 3479) CNRS Aix-Marseille Université, 163 Avenue de Luminy, Case 934, 13288 Marseille cedex 9, France
| | - Françoise Debart
- IBMM, UMR 5247, CNRS-UM1-UM2, Université Montpellier 2, Place Eugène Bataillon, 34095 Montpellier, France
| | - Jean-Michel Claverie
- Structural and Genomic Information Laboratory, UMR 7256 (IMM FR 3479) CNRS Aix-Marseille Université, 163 Avenue de Luminy, Case 934, 13288 Marseille cedex 9, France APHM, FR-13385 Marseille, France
| | - Chantal Abergel
- Structural and Genomic Information Laboratory, UMR 7256 (IMM FR 3479) CNRS Aix-Marseille Université, 163 Avenue de Luminy, Case 934, 13288 Marseille cedex 9, France
| |
Collapse
|
24
|
Potisopon S, Priet S, Collet A, Decroly E, Canard B, Selisko B. The methyltransferase domain of dengue virus protein NS5 ensures efficient RNA synthesis initiation and elongation by the polymerase domain. Nucleic Acids Res 2014; 42:11642-56. [PMID: 25209234 PMCID: PMC4191377 DOI: 10.1093/nar/gku666] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Viral RNA-dependent RNA polymerases (RdRps) responsible for the replication of single-strand RNA virus genomes exert their function in the context of complex replication machineries. Within these replication complexes the polymerase activity is often highly regulated by RNA elements, proteins or other domains of multi-domain polymerases. Here, we present data of the influence of the methyltransferase domain (NS5-MTase) of dengue virus (DENV) protein NS5 on the RdRp activity of the polymerase domain (NS5-Pol). The steady-state polymerase activities of DENV-2 recombinant NS5 and NS5-Pol are compared using different biochemical assays allowing the dissection of the de novo initiation, transition and elongation steps of RNA synthesis. We show that NS5-MTase ensures efficient RdRp activity by stimulating the de novo initiation and the elongation phase. This stimulation is related to a higher affinity of NS5 toward the single-strand RNA template indicating NS5-MTase either completes a high-affinity RNA binding site and/or promotes the correct formation of the template tunnel. Furthermore, the NS5-MTase increases the affinity of the priming nucleotide ATP upon de novo initiation and causes a higher catalytic efficiency of the polymerase upon elongation. The complex stimulation pattern is discussed under the perspective that NS5 adopts several conformations during RNA synthesis.
Collapse
Affiliation(s)
- Supanee Potisopon
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Stéphane Priet
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Axelle Collet
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Etienne Decroly
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Bruno Canard
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| | - Barbara Selisko
- Aix-Marseille Université, AFMB UMR 7257, 13288 Marseille, France CNRS, AFMB UMR 7257, 13288 Marseille, France
| |
Collapse
|
25
|
Potisopon S, Priet S, Selisko B, Canard B. Comparison of dengue virus and HCV: from impact on global health to their RNA-dependent RNA polymerases. Future Virol 2014. [DOI: 10.2217/fvl.13.121] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
ABSTRACT: Upon the discovery of HCV, dengue virus (DENV) and other flaviviruses have served as models to unravel the biology and mechanisms at play during HCV replication. HCV research has rapidly become a well-established field. Recently, several specific anti-HCV antiviral drugs have been discovered and approved for use in the clinic. Now, the strong emergence of DENV in the world and the associated increasing burden is casting light back to dengue virology and anti-dengue drug discovery. HCV polymerase (NS5B) is a prime target in antiviral therapies, and the analogous DENV polymerase (NS5) is also becoming one. Although both enzymes share common fold and function to some extent, a significant amount of unique structural and functional features have to be clearly delineated to efficiently translate drug design potential between these two essential enzymes.
Collapse
Affiliation(s)
- Supanee Potisopon
- AFMB Laboratoire d’Architecture et Fonction des Macromolécules Biologiques, Aix-Marseille Université & CNRS, UMR 7257, Parc Scientifique et Technologique de Luminy, Case 932, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France
| | - Stéphane Priet
- AFMB Laboratoire d’Architecture et Fonction des Macromolécules Biologiques, Aix-Marseille Université & CNRS, UMR 7257, Parc Scientifique et Technologique de Luminy, Case 932, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France
| | - Barbara Selisko
- AFMB Laboratoire d’Architecture et Fonction des Macromolécules Biologiques, Aix-Marseille Université & CNRS, UMR 7257, Parc Scientifique et Technologique de Luminy, Case 932, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France
| | - Bruno Canard
- AFMB Laboratoire d’Architecture et Fonction des Macromolécules Biologiques, Aix-Marseille Université & CNRS, UMR 7257, Parc Scientifique et Technologique de Luminy, Case 932, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France
| |
Collapse
|
26
|
Roux L, Priet S, Payrot N, Weck C, Fournier M, Zoulim F, Balzarini J, Canard B, Alvarez K. Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. Eur J Med Chem 2013; 63:869-81. [PMID: 23603046 DOI: 10.1016/j.ejmech.2013.02.039] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2012] [Revised: 01/30/2013] [Accepted: 02/26/2013] [Indexed: 12/25/2022]
Abstract
9-[2-(Thiophosphonomethoxy)ethyl]adenine [S-PMEA, 8] and (R)-9-[2-(Thiophosphonomethoxy)propyl]adenine [S-PMPA, 9] are acyclic nucleoside thiophosphonates we described recently that display the same antiviral spectrum (DNA viruses) as approved and potent phosphonates PMEA and (R)-PMPA. Here, we describe the synthesis, antiviral activities in infected cell cultures and decomposition study of bis(pivaloyloxymethoxy)-S-PMEA [Bis-POM-S-PMEA, 13] and bis(isopropyloxymethylcarbonyl)-S-PMPA [Bis-POC-S-PMPA, 14] as orally bioavailable prodrugs of the S-PMEA 8 and S-PMPA 9, in comparison to the equivalent "non-thio" derivatives [Bis-POM-PMEA, 11] and [Bis-POC-PMPA, 12]. Compounds 11, 12, 13 and 14 were evaluated for their in vitro antiviral activity against HIV-1-, HIV-2-, HBV- and a broad panel of DNA viruses, and found to exhibit moderate to potent antiviral activity. In order to determine the decomposition pathway of the prodrugs 11, 12, 13 and 14 into parent compounds PMEA, PMPA, 8 and 9, kinetic data and decomposition pathways in several media are presented. As expected, bis-POM-S-PMEA 13 and bis-POC-S-PMPA 14 behaved as prodrugs of S-PMEA 8 and S-PMPA 9. However, thiophosphonates 8 and 9 were released very smoothly in cell extracts, in contrast to the release of PMEA and PMPA from "non-thio" prodrugs 11 and 12.
Collapse
Affiliation(s)
- Loïc Roux
- Laboratoire d'Architecture et Fonction des Macromolécules Biologiques, UMR CNRS 7257, Equipe Chimie Médicinale et Virologie Structurale, Université Aix-Marseille, Parc scientifique de Luminy, 163 av. de Luminy, 13288 Marseille Cedex 9, France
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Selisko B, Potisopon S, Agred R, Priet S, Varlet I, Thillier Y, Sallamand C, Debart F, Vasseur JJ, Canard B. Molecular basis for nucleotide conservation at the ends of the dengue virus genome. PLoS Pathog 2012; 8:e1002912. [PMID: 23028313 PMCID: PMC3441707 DOI: 10.1371/journal.ppat.1002912] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2012] [Accepted: 08/03/2012] [Indexed: 12/02/2022] Open
Abstract
The dengue virus (DV) is an important human pathogen from the Flavivirus genus, whose genome- and antigenome RNAs start with the strictly conserved sequence pppAG. The RNA-dependent RNA polymerase (RdRp), a product of the NS5 gene, initiates RNA synthesis de novo, i.e., without the use of a pre-existing primer. Very little is known about the mechanism of this de novo initiation and how conservation of the starting adenosine is achieved. The polymerase domain NS5PolDV of NS5, upon initiation on viral RNA templates, synthesizes mainly dinucleotide primers that are then elongated in a processive manner. We show here that NS5PolDV contains a specific priming site for adenosine 5′-triphosphate as the first transcribed nucleotide. Remarkably, in the absence of any RNA template the enzyme is able to selectively synthesize the dinucleotide pppAG when Mn2+ is present as catalytic ion. The T794 to A799 priming loop is essential for initiation and provides at least part of the ATP-specific priming site. The H798 loop residue is of central importance for the ATP-specific initiation step. In addition to ATP selection, NS5PolDV ensures the conservation of the 5′-adenosine by strongly discriminating against viral templates containing an erroneous 3′-end nucleotide in the presence of Mg2+. In the presence of Mn2+, NS5PolDV is remarkably able to generate and elongate the correct pppAG primer on these erroneous templates. This can be regarded as a genomic/antigenomic RNA end repair mechanism. These conservational mechanisms, mediated by the polymerase alone, may extend to other RNA virus families having RdRps initiating RNA synthesis de novo. The 5′- and 3′-ends of RNA virus genomes have evolved towards efficient replication, translation, and escape from defense mechanisms of the host cell. Little is known about how RNA viruses conserve or restore the correct ends of their genomes. The Flavivirus genus of positive-strand RNA viruses contains important human pathogens such as yellow fever virus, West Nile virus, Japanese encephalitis virus and dengue virus (DV). The Flavivirus genome ends are strictly conserved as 5′-AG…CU-3′. We demonstrate here the primary role of the DV polymerase in the conservation of the first and last genomic residue. We show that DV polymerase contains an ATP-specific priming site, which imposes a strong preference for the de novo synthesis of a dinucleotide primer starting with an ATP. Furthermore, the polymerase is able to indirectly correct erroneous sequences by producing the correct primer in the absence of template and on templates containing incorrect nucleotides at the 3′-end. The correct primer is productively elongated on either correct or incorrect templates. Our findings provide a direct demonstration of the implication of a viral RNA polymerase in the conservation and repair of genome ends. Other polymerases from other RNA virus families are likely to employ similar mechanisms.
Collapse
Affiliation(s)
- Barbara Selisko
- Aix-Marseille Université, CNRS, AFMB UMR 7257, 163, Marseille, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F. Erratum: SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012. [DOI: 10.1038/ni0612-621c] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Barral K, Weck C, Payrot N, Roux L, Durafour C, Zoulim F, Neyts J, Balzarini J, Canard B, Priet S, Alvarez K. Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication. Eur J Med Chem 2011; 46:4281-8. [PMID: 21803462 PMCID: PMC7115536 DOI: 10.1016/j.ejmech.2011.06.034] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2011] [Revised: 06/21/2011] [Accepted: 06/22/2011] [Indexed: 12/31/2022]
Abstract
9-[2-(Thiophosphonomethoxy)ethyl]adenine 3 and (R)-9-[2-(Thiophosphonomethoxy)propyl]adenine 4 were synthesized as the first thiophosphonate nucleosides bearing a sulfur atom at the α-position of the acyclic nucleoside phosphonates PMEA and PMPA. Thiophosphonates S-PMEA 3 and S-PMPA 4 were evaluated for in vitro activity against HIV-1 (subtypes A to G), HIV-2 and HBV-infected cells, and found to exhibit potent antiretroviral activity. We showed that their diphosphate forms S-PMEApp 5 and S-PMPApp 6 are readily incorporated by wild-type (WT) HIV-1 RT into DNA and act as DNA chain terminators. Compounds 3 and 4 were evaluated for in vitro activity against a broad panel of DNA and RNA viruses and displayed beside HIV a moderate activity against herpes simplex virus and vaccinia viruses. In order to measure enzymatic stabilities of the target derivatives 3 and 4, kinetic data and decomposition pathways were studied at 37 °C in several media.
Collapse
Affiliation(s)
- Karine Barral
- Laboratoire d'Architecture et Fonction des Macromolécules Biologiques, UMR CNRS 6098, Equipe Réplicases Virales: Structure, Mécanisme, et Drug-design, Universités Aix-Marseille I et II, Parc scientifique de Luminy, 163 av de Luminy, 13288 Marseille Cedex 9, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Priet S, Zlatev I, Barvik I, Neyts J, Dutartre H, Canard B, Morvan F, Alvarez K. Phosphoramidate Dinucleosides as Inhibitors of Hepatitis C Virus Subgenomic Replicon and NS5B Polymerase Activity. Antiviral Res 2011. [DOI: 10.1016/j.antiviral.2011.03.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Barral K, Priet S, De Michelis C, Sire J, Neyts J, Balzarini J, Canard B, Alvarez K. Synthesis and antiviral activity of boranophosphonate isosteres of AZT and d4T monophosphates. Eur J Med Chem 2010; 45:849-56. [DOI: 10.1016/j.ejmech.2009.11.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2007] [Revised: 10/28/2009] [Accepted: 11/05/2009] [Indexed: 10/20/2022]
|
32
|
Esnault C, Priet S, Ribet D, Heidmann O, Heidmann T. Restriction by APOBEC3 proteins of endogenous retroviruses with an extracellular life cycle: ex vivo effects and in vivo "traces" on the murine IAPE and human HERV-K elements. Retrovirology 2008; 5:75. [PMID: 18702815 PMCID: PMC2531183 DOI: 10.1186/1742-4690-5-75] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2008] [Accepted: 08/14/2008] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND APOBEC3 cytosine deaminases have been demonstrated to restrict infectivity of a series of retroviruses, with different efficiencies depending on the retrovirus. In addition, APOBEC3 proteins can severely restrict the intracellular transposition of a series of retroelements with a strictly intracellular life cycle, including the murine IAP and MusD LTR-retrotransposons. RESULTS Here we show that the IAPE element, which is the infectious progenitor of the strictly intracellular IAP elements, and the infectious human endogenous retrovirus HERV-K are restricted by both murine and human APOBEC3 proteins in an ex vivo assay for infectivity, with evidence in most cases of strand-specific G-to-A editing of the proviruses, with the expected signatures. In silico analysis of the naturally occurring genomic copies of the corresponding endogenous elements performed on the mouse and human genomes discloses "traces" of APOBEC3-editing, with the specific signature of the murine APOBEC3 and human APOBEC3G enzymes, respectively, and to a variable extent depending on the family member. CONCLUSION These results indicate that the IAPE and HERV-K elements, which can only replicate via an extracellular infection cycle, have been restricted at the time of their entry, amplification and integration into their target host genomes by definite APOBEC3 proteins, most probably acting in evolution to limit the mutagenic effect of these endogenized extracellular parasites.
Collapse
Affiliation(s)
- Cécile Esnault
- Unité des Rétrovirus Endogènes et Eléments Rétroïdes des Eucaryotes Supérieurs, CNRS UMR 8122, Institut Gustave Roussy, 39 rue Camille Desmoulins, F-94805 Villejuif, and Université Paris-Sud, Orsay, F-91405, France
| | - Stéphane Priet
- Unité des Rétrovirus Endogènes et Eléments Rétroïdes des Eucaryotes Supérieurs, CNRS UMR 8122, Institut Gustave Roussy, 39 rue Camille Desmoulins, F-94805 Villejuif, and Université Paris-Sud, Orsay, F-91405, France
- Architecture et Fonction des Macromolécules Biologiques, CNRS UMR 6098, ESIL case 925, F-13288 Marseille Cedex 9, France
| | - David Ribet
- Unité des Rétrovirus Endogènes et Eléments Rétroïdes des Eucaryotes Supérieurs, CNRS UMR 8122, Institut Gustave Roussy, 39 rue Camille Desmoulins, F-94805 Villejuif, and Université Paris-Sud, Orsay, F-91405, France
- Unité des interactions Bactéries-Cellules, INSERM U604, INRA USC2020, Institut Pasteur, 25 rue du Dr Roux, F-75024 Paris Cedex 15, France
| | - Odile Heidmann
- Unité des Rétrovirus Endogènes et Eléments Rétroïdes des Eucaryotes Supérieurs, CNRS UMR 8122, Institut Gustave Roussy, 39 rue Camille Desmoulins, F-94805 Villejuif, and Université Paris-Sud, Orsay, F-91405, France
| | - Thierry Heidmann
- Unité des Rétrovirus Endogènes et Eléments Rétroïdes des Eucaryotes Supérieurs, CNRS UMR 8122, Institut Gustave Roussy, 39 rue Camille Desmoulins, F-94805 Villejuif, and Université Paris-Sud, Orsay, F-91405, France
| |
Collapse
|
33
|
Abstract
Uracil is a natural base of RNA but may appear in DNA through two different pathways including cytosine deamination or misincorporation of deoxyuridine 5'-triphosphate nucleotide (dUTP) during DNA replication and constitutes one of the most frequent DNA lesions. In cellular organisms, such lesions are faithfully cleared out through several universal DNA repair mechanisms, thus preventing genome injury. However, several recent studies have brought some pieces of evidence that introduction of uracil bases in viral genomic DNA intermediates during genome replication might be a way of innate immune defence against some viruses. As part of countermeasures, numerous viruses have developed powerful strategies to prevent emergence of uracilated viral genomes and/or to eliminate uracils already incorporated into DNA. This review will present the current knowledge about the cellular and viral countermeasures against uracils in DNA and the implications of these uracils as weapons against viruses.
Collapse
Affiliation(s)
- Joséphine Sire
- UMR IRD-190, Emergence des Pathologies Virales, Faculté de Médecine, 27 Bd Jean Moulin, 13005 Marseille, France.
| | | | | | | |
Collapse
|
34
|
Barral K, Priet S, Sire J, Neyts J, Balzarini J, Canard B, Alvarez K. Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. J Med Chem 2007; 49:7799-806. [PMID: 17181162 DOI: 10.1021/jm060030y] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We describe here the synthesis of 9-[2-(boranophosphonomethoxy)ethyl]adenine (6a) and (R)-9-[2-(boranophosphonomethoxy)propyl]adenine (6b), the first alpha-boranophosphonate nucleosides in which a borane (BH3) group substitutes one nonbridging oxygen atom of the alpha-phosphonate moiety. H-phosphinates 5a and 5b and alpha-boranophosphonates 6a and 6b were evaluated for their in vitro activity against human immunodeficiency virus (HIV) infected cells and against a panel of DNA or RNA viruses. Compounds 5a, 5b, 6a, and 6b exhibited no significant antiviral activity in vitro and cytotoxicity. To measure the chemical and enzymatic stabilities of the target compounds 6a and 6b, kinetic data of decomposition for derivatives 5a, 5b, 6a, 6b, and standard compounds were studied at 37 degrees C in several media. The alpha-boranophosphonates 6a and 6b were metabolized in culture medium into H-phosphinates 5a and 5b, with half-live values of 5.3 h for 6a and 1.3 h for 6b.
Collapse
Affiliation(s)
- Karine Barral
- Laboratoire d'Architecture et Fonction des Macromolécules Biologiques, UMR CNRS 6098, Universités Aix-Marseille I et II, Parc scientifique de Luminy, 163 av. de Luminy, 13288 Marseille Cedex 9, France
| | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Uracil in DNA is a deleterious event that may arise either by cytosine deamination or misincorporation of dUTP. Consequently, cells from all free-living organisms have developed strategies to protect their genome against the presence of uracils, by using uracil DNA glycosylase (UNG) and deoxyuridine triphosphatase (dUTPase) enzymatic activities. In the viral kingdom, some (namely poxviruses and herpesviruses) but not all of the DNA viruses encode their own UNG and dUTPase to control uracilation of their genome. Some retroviruses, which are RNA viruses using DNA as an intermediate of replication, also encode dUTPase. Surprisingly, though most of nonprimate lentiviruses encode dUTPase, primate lentiviruses such as HIV-1, HIV-2 or SIV do not. Because these latter viruses also replicate in nondividing cells where the dUTP/dTTP ratio is high, it is probable that they have found other ways to fight against the emergence of uracilated-viral transcripts. Indeed, recent studies showed that HIV-1 efficiently controls both the cytosine deamination and the dUTP misincorporation. The viral Vif protein acts in preventing the packaging into viral particles of the host-derived cytosine deaminase APOBEC3G enzyme, while the viral integrase domain of the Gag-Pol precursor mediates the packaging of the host-derived uracil DNA glycosylase UNG2 enzyme. In the absence of Vif or UNG2, HIV-1 viral transcripts are heavily charged in uracil bases leading to inactivation of the virus.
Collapse
Affiliation(s)
- Stéphane Priet
- Unitédes Virus Emergents, Facultéde Médecine, 27 Boulevard Jean Moulin, 13385 Marseille Cedex 5, France
| | | | | |
Collapse
|
36
|
Priet S, Gros N, Navarro JM, Boretto J, Canard B, Quérat G, Sire J. HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle. Mol Cell 2005; 17:479-90. [PMID: 15721252 DOI: 10.1016/j.molcel.2005.01.016] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2004] [Revised: 11/26/2004] [Accepted: 01/21/2005] [Indexed: 01/13/2023]
Abstract
Uracilation of DNA represents a constant threat to the survival of many organisms including viruses. Uracil may appear in DNA either by cytosine deamination or by misincorporation of dUTP. The HIV-1-encoded Vif protein controls cytosine deamination by preventing the incorporation of host-derived APOBEC3G cytidine deaminase into viral particles. Here, we show that the host-derived uracil DNA glycosylase UNG2 enzyme, which is recruited into viral particles by the HIV-1-encoded integrase domain, is essential to the viral life cycle. We demonstrate that virion-associated UNG2 catalytic activity can be replaced by the packaging of heterologous dUTPase into virion, indicating that UNG2 acts to counteract dUTP misincorporation in the viral genome. Therefore, HIV-1 prevents incorporation of dUTP in viral cDNA by UNG2-mediated uracil excision followed by a dNTP-dependent, reverse transcriptase-mediated endonucleolytic cleavage and finally by strand-displacement polymerization. Our findings indicate that pharmacologic strategies aimed toward blocking UNG2 packaging should be explored as potential HIV/AIDS therapeutics.
Collapse
Affiliation(s)
- Stéphane Priet
- Pathogénie des Infections à Lentivirus, INSERM U372, Université de la Méditerranée, 163 Avenue de Luminy, BP 178, 13276 Marseille Cedex 9, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Violot S, Hong SS, Rakotobe D, Petit C, Gay B, Moreau K, Billaud G, Priet S, Sire J, Schwartz O, Mouscadet JF, Boulanger P. The human polycomb group EED protein interacts with the integrase of human immunodeficiency virus type 1. J Virol 2003; 77:12507-22. [PMID: 14610174 PMCID: PMC262565 DOI: 10.1128/jvi.77.23.12507-12522.2003] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2003] [Accepted: 08/23/2003] [Indexed: 11/20/2022] Open
Abstract
Human EED, a member of the superfamily of WD-40 repeat proteins and of the Polycomb group proteins, has been identified as a cellular partner of the human immunodeficiency virus type 1 (HIV-1) matrix (MA) protein (R. Peytavi et al., J. Biol. Chem. 274:1635-1645, 1999). In the present study, EED was found to interact with HIV-1 integrase (IN) both in vitro and in vivo in yeast. In vitro, data from mutagenesis studies, pull-down assays, and phage biopanning suggested that EED-binding site(s) are located in the C-terminal domain of IN, between residues 212 and 264. In EED, two putative discrete IN-binding sites were mapped to its N-terminal moiety, at a distance from the MA-binding site, but EED-IN interaction also required the integrity of the EED last two WD repeats. EED showed an apparent positive effect on IN-mediated DNA integration reaction in vitro, in a dose-dependent manner. In situ analysis by immunoelectron microscopy (IEM) of cellular distribution of IN and EED in HIV-1-infected cells (HeLa CD4(+) cells or MT4 lymphoid cells) showed that IN and EED colocalized in the nucleus and near nuclear pores, with maximum colocalization events occurring at 6 h postinfection (p.i.). Triple colocalizations of IN, EED, and MA were also observed in the nucleoplasm of infected cells at 6 h p.i., suggesting the ocurrence of multiprotein complexes involving these three proteins at early steps of the HIV-1 virus life cycle. Such IEM patterns were not observed with a noninfectious, envelope deletion mutant of HIV-1.
Collapse
Affiliation(s)
- Sébastien Violot
- Laboratoire de Virologie and Pathogénèse Virale, Faculté de Médecine RTH Laennec, CNRS UMR-5537, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Priet S, Navarro JM, Quérat G, Sire J. Reversion of the lethal phenotype of an HIV-1 integrase mutant virus by overexpression of the same integrase mutant protein. J Biol Chem 2003; 278:20724-30. [PMID: 12670953 DOI: 10.1074/jbc.m301768200] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The human immunodeficiency virus type 1 (HIV-1) integrase (IN) is essential for integration of viral DNA into host cell chromatin. We have reported previously (Priet, S., Navarro, J. M., Gros, N., Querat, G., and Sire, J. (2003) J. Biol. Chem. 278, 4566-4571) that IN also plays a role in the packaging of the host uracil DNA glycosylase UNG2 into viral particles and that the region of IN encompassing residues 170-180 was responsible for the interaction with UNG2 and for its packaging into virions. In this work, we aimed to investigate the replication of HIV-1 viruses rendered deficient in virion-associated UNG2 by single or double point mutations in the region 170-180 of IN. We show that the L172A/K173A IN mutant virus was deficient for UNG2 packaging and was defective for replication because of a blockage at the stage of proviral DNA integration in host cell DNA. In vitro assays using long term repeat mimics, however, demonstrate that the L172A/K173A IN mutant was catalytically active. Moreover, trans-complementation experiments show that the viral propagation of L172A/K173A viruses could be rescued by the overexpression of Vpr.L172A/K173A IN fusion protein in a dose-dependent manner and that this rescue is independent of UNG2 packaging. Altogether, our data indicate that L172A/K173A mutations of IN induce a subtle defect in the function of IN, which nevertheless dramatically impairs viral replication. Unexpectedly, this blockage of replication could be overcome by forcing the packaging of higher amounts of this same mutated integrase. This is the first study reporting that blockage of the integration process of HIV-1 provirus carrying a mutation of IN could be alleviated by increasing amounts of IN even carrying the same mutations.
Collapse
Affiliation(s)
- Stéphane Priet
- Pathogénie des Infections à Lentivirus, INSERM U372, 163 Avenue de Luminy, BP 178, 13276 Marseille-Cedex 9, France
| | | | | | | |
Collapse
|
39
|
Abstract
We have previously reported that the host uracil DNA glycosylase UNG2 enzyme is incorporated into HIV-1 virions via a specific association with the viral integrase (IN) domain of Gag-Pol precursor. In this study, we investigated whether UNG2 was packaged into two phylogenetically closely related primate lentiviruses, HIV-2(ROD) and SIV(MAC239). We demonstrated by GST-pull-down and coprecipitation assays that INs from HIV-1, HIV-2(ROD), and SIV(MAC239) associated with UNG2, although the interaction of UNG2 with HIV-2(ROD) IN and SIV(MAC239) IN was less strong than with HIV-1 IN. We then showed by Western blotting that highly purified HIV-2 and SIV(MAC) viral particles did not incorporate host UNG2, contrasting with the presence of UNG2 in HIV-1 viral particles. Finally, we showed that HIV-1/SIV chimeric viruses in which residues 6 to 202 of HIV-1 IN were replaced by the SIV counterpart were impaired for packaging of UNG2, indicating that the incorporation of host UNG2 into viral particles is the hallmark of the HIV-1 strain. Moreover, we found that HIV-1/SIV IN chimeric viruses were deficient for viral propagation.
Collapse
Affiliation(s)
- Stéphane Priet
- Pathogénie des Infections à Lentivirus, INSERM U372, Marseille, France
| | | | | | | | | |
Collapse
|
40
|
Navarro JM, Damier L, Boretto J, Priet S, Canard B, Quérat G, Sire J. Glutamic residue 438 within the protease-sensitive subdomain of HIV-1 reverse transcriptase is critical for heterodimer processing in viral particles. Virology 2001; 290:300-8. [PMID: 11883194 DOI: 10.1006/viro.2001.1188] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The biological form of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is a heterodimer consisting of two polypeptides, p66 and p51, which have identical N-termini. The p51 polypeptide is generated by action of viral protease cleaving the p66 polypeptide between residues Phe440 and Tyr441. Dimerization has been mostly studied using bacterially purified RT bearing amino acid changes in either subunit, but not in the context of HIV-1 particles. We introduced changes of conserved amino acid residues 430-438 into the protease-sensitive subdomain of the p66 subunit and analyzed the reverse transcriptase processing and function using purified variants and their corresponding HIV-1 recombinant clones. Our mutational analysis shows that the conserved Glu438 residue is critical for proper heterodimerization and function of virion-associated RT, but not of bacterially expressed RT. In contrast, the conserved Glu430, Glu432, and Pro433 residues are not important for dimerization of virion-associated RT. The network of interactions made by the Glu438 carboxyl group with neighboring residues is critical to protect the Phe440-Tyr441 from cleavage in the context of the p66/p51 heterodimer and may explain why the p66/p51 is not processed further to p51/p51.
Collapse
Affiliation(s)
- J M Navarro
- INSERM U372, 163 avenue de Luminy, BP 178, 13276 Marseille, France
| | | | | | | | | | | | | |
Collapse
|